Sanofi-Aventis recently admitted it needed to increase the number
of biotech compounds in its pipeline and now, true to its word, the
French pharma heavyweight has signed a big antibody deal with US
biotech Regeneron.
Rumours that Pfizer is looking into buying a large stake in
Sanofi-Aventis, which could be seen as a prelude to a full takeover
bid, has prompted a flurry of shareholder activity.
At this week's research and development (R&D) day in Paris,
Sanofi-Aventis gave a comprehensive update of its pipeline.
DrugResearcher.com was there to bring you the highlights.
Sanofi-Aventis' disposable insulin pen SoloStar has been launched
across the US for use with the company's 24-hour basal insulin
Lantus (insulin glargine), despite patent infringement claims
emanating from fellow insulin...
An exclusive license to a late stage product has enabled
Sanofi-aventis to up the stakes in a bid to be the first company to
release a dedicated cancer vaccine.
Sanofi-Aventis is gearing up for the European roll-out of a new
disposable insulin pen designed to address a broader spectrum of
patient needs than currently available injection devices.
Sanofi pasteur's vaccine manufacturing plant in Pennsylvania, where
half of America's influenza vaccines are made, has been served with
a warning letter by the US Food and Drug Administration (FDA),
asking for measures to...
Looking to establish itself in Eastern Europe, French drug maker
Sanofi-Aventis has bought a 24.9 per cent stake in Czech generic
drug firm Zentiva for $514.7m (€430m).
Sanofi Pasteur has entered into a license and supply agreement with
Eisai for the use of their novel adjuvant designed to boost the
immune response to a broad range of vaccines.
France's Sanofi-Synthelabo has announced plans to sell two of its
products to GlaxoSmithKline in a deal which forms part of its
strategy to take over Aventis.
Sanofi's hostile bid for larger French rival Aventis may have been
rejected, but there are a number of arguments in favour of a link,
according to analyst Nicole Lamble at market research firm
Datamonitor.